Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Aggression × Ifosfamide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 46 Lymphoma 34 Lymphoma, Large B-Cell, Diffuse 24 Lymphoma, Non-Hodgkin 18 Hodgkin Disease 17 Precursor Cell Lymphoblastic Leukemia-Lymphoma 16 Osteosarcoma 15 Testicular Neoplasms 13 Leukemia 13 Lymphoma, Large-Cell, Immunoblastic 12 Lymphoma, Follicular 12 Burkitt Lymphoma 12 Ovarian Neoplasms 11 Lymphoma, Mantle-Cell 10 Testicular Germ Cell Tumor 8 Sarcoma, Synovial 8 Recurrence 8 Neurofibrosarcoma 8 Neuroectodermal Tumors, Primitive, Peripheral 8 Lymphoma, B-Cell, Marginal Zone 8 Liposarcoma 8 Leukemia, Lymphocytic, Chronic, B-Cell 8 Leiomyosarcoma 8 Histiocytoma, Malignant Fibrous 8 Hemangiosarcoma 8 Fibrosarcoma 8 Rhabdomyosarcoma 7 Lymphoma, Large-Cell, Anaplastic 7 Teratoma 6 Neoplasms 6

Interventions

vandetanib 1 selinexor 1 pegfilgrastim 1 midostaurin 1 Topotecan 1 Rituximab 1 Prednisone 1 Paclitaxel 1 Methylprednisolone 1 Immunologic Techniques 1 Ifosfamide 1 Flow Cytometry 1 Etoposide 1 Dexamethasone 1 Carboplatin 1 Alemtuzumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02471911 2022-04-12

KPT-330+RICE

Weill Medical College of Cornell University

Phase 1 Completed

Aggression, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon ⚡